

## Seeking opportunities for products to prevent and treat cardio-metabolic and other diseases

Caelus Health is an innovative company based in Amsterdam, the Netherlands, dedicated to the development and commercialization of microbiota-based products to prevent and treat cardio-metabolic and other diseases.



### Interests and Challenges

To bridge the gap between research and commercialization, Caelus Health is interested in:

1. Research partners to study the potential of *A. soehngenii*/*E. hallii* as GLP-1 agonist in the fight against obesity
2. Academic and innovative partners to enhance stability of microbiota products based on single strains or broad consortia of (mainly) anaerobic strains
3. Industry partners to register and commercialize Live Biotherapeutic Products (LBPs) from our strong pipeline of evidence-based and well protected strains

### Areas of Development

#### *A. soehngenii* (= *E. hallii*)

Anaerobic strain, producing butyrate, GLP-1 agonist

- This strain was identified in a fmt-study in pre-diabetes Following preclinical testing, clinical development started.
- The 4th clinical trial in (pre-)diabetes has been completed.
- Toxicology studies demonstrated safety and resulted in GRAS and Novel Food filings.
- Key patents have been issued.

#### *A. rhamnosivorans*

Anaerobic strain

- This strain was also discovered by the team in Wageningen.
- It is in the preclinical phase of development.

#### *I. butyriciproducens*

Anaerobic strain, producing butyrate

- This strain was discovered by the team in Wageningen and has been studied extensively in preclinical models.
- The first clinical Proof-of-Concept study in pre-diabetes is ongoing.
- Key patents have been issued worldwide.

#### FMT applications

Whole consortia

- Successful clinical use of FMT in Type 1 diabetes, Cancer, cachexia and NAFLD/NASH; range of 5 patents

[SUBMIT OPPORTUNITIES](#)

